Zydus Lifesciences Limited

NSEI:ZYDUSLIFE Stock Report

Market Cap: ₹1.0t

Zydus Lifesciences Future Growth

Future criteria checks 0/6

Zydus Lifesciences is forecast to grow earnings and revenue by 0.4% and 6.4% per annum respectively. EPS is expected to grow by 0.5% per annum. Return on equity is forecast to be 16.1% in 3 years.

Key information

0.4%

Earnings growth rate

0.5%

EPS growth rate

Pharmaceuticals earnings growth17.3%
Revenue growth rate6.4%
Future return on equity16.1%
Analyst coverage

Good

Last updated17 Jan 2025

Recent future growth updates

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 15
Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14
Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Recent updates

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Might Deserve Your Attention Today

Dec 16
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Might Deserve Your Attention Today

These 4 Measures Indicate That Zydus Lifesciences (NSE:ZYDUSLIFE) Is Using Debt Safely

Nov 30
These 4 Measures Indicate That Zydus Lifesciences (NSE:ZYDUSLIFE) Is Using Debt Safely

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 15
Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Sep 14
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Aug 30
Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14
Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 03
Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Jul 19
Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 05
Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Jun 20
Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Jun 10
Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

May 25
Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Mar 18
Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28
Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12
Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Earnings and Revenue Growth Forecasts

NSEI:ZYDUSLIFE - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027253,05142,89340,47349,83725
3/31/2026243,46446,09041,43051,66028
3/31/2025227,63344,63932,22743,95229
9/30/2024214,83542,77731,78345,938N/A
6/30/2024206,15341,685N/AN/AN/A
3/31/2024195,47438,36523,21332,279N/A
12/31/2023190,24129,562N/AN/AN/A
9/30/2023187,76028,10928,07837,726N/A
6/30/2023184,12725,262N/AN/AN/A
3/31/2023172,37419,64916,57926,888N/A
12/31/2022164,33520,785N/AN/AN/A
9/30/2022157,11019,6298,93420,209N/A
6/30/2022153,36121,710N/AN/AN/A
3/31/2022151,09922,41610,14621,045N/A
12/31/2021157,60923,267N/AN/AN/A
9/30/2021157,38923,26917,28328,059N/A
6/30/2021156,13022,600N/AN/AN/A
3/31/2021144,03522,01624,39932,939N/A
12/31/2020150,07618,465N/AN/AN/A
9/30/2020148,50116,93218,75727,798N/A
6/30/2020143,96713,270N/AN/AN/A
3/31/2020142,53111,76620,27429,315N/A
12/31/2019142,33812,448N/AN/AN/A
9/30/2019141,73613,81626,55334,629N/A
6/30/2019137,68216,919N/AN/AN/A
3/31/2019131,65618,4882,24512,819N/A
12/31/2018126,70619,954N/AN/AN/A
9/30/2018123,52620,305N/AN/AN/A
6/30/2018126,13321,168N/AN/AN/A
3/31/2018119,04917,946N/A9,193N/A
12/31/2017111,69115,705N/AN/AN/A
9/30/2017102,20613,511N/AN/AN/A
6/30/201793,39712,277N/AN/AN/A
3/31/201793,76514,904N/A13,117N/A
12/31/201697,49411,323N/AN/AN/A
9/30/201697,97112,812N/AN/AN/A
6/30/201697,22114,186N/AN/AN/A
3/31/201694,26819,339N/A18,935N/A
12/31/201595,90114,843N/AN/AN/A
9/30/201592,45313,766N/AN/AN/A
6/30/201589,79512,638N/AN/AN/A
3/31/201586,51311,506N/A9,936N/A
12/31/201482,95510,394N/AN/AN/A
9/30/201479,7779,435N/AN/AN/A
6/30/201476,1658,488N/AN/AN/A
3/31/201472,0348,036N/A9,028N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYDUSLIFE's forecast earnings growth (0.4% per year) is below the savings rate (6.7%).

Earnings vs Market: ZYDUSLIFE's earnings (0.4% per year) are forecast to grow slower than the Indian market (17.9% per year).

High Growth Earnings: ZYDUSLIFE's earnings are forecast to grow, but not significantly.

Revenue vs Market: ZYDUSLIFE's revenue (6.4% per year) is forecast to grow slower than the Indian market (10.7% per year).

High Growth Revenue: ZYDUSLIFE's revenue (6.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ZYDUSLIFE's Return on Equity is forecast to be low in 3 years time (16.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 12:28
End of Day Share Price 2025/01/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zydus Lifesciences Limited is covered by 70 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited